Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug ...
Investigators compared outcomes among patients with psoriasis undergoing apremilast treatment with genital involvement versus those without genital involvement.
The "Enterprise Tech Ecosystem Series: Almirall - 2025" company profile has been added to ResearchAndMarkets.com's offering. The report provides insights into the Almirall's tech activities, including ...
Investor's Business Daily on MSN4d
Why IBD 50's Arcutis Is Outplaying The Biotech Tape And Just Reentered Its Buy ZoneArcutis Biotherapeutics wants to eliminate a terrible trade-off for patients with skin conditions. Arcutis stock investors are taking notice.
LEO Pharma and Reig Jofre have entered into a partnership aimed at improving access to LEO’s psoriasis treatment in Europe.
STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was launched on March 12, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback